Skip to main content
<p>Patients with type 2 diabetes at high risk for cardiovascular disease who received empagliflozin had significantly lower rates of the composite cardiac vascular outcome and death from any cause.</p>

Diabetes Drug Reduces Heart Failure, Cardiovascular Death Risk